NEW YORK ( TheStreet) -- CHANGE IN RATINGSAmgen ( AMGN) upgraded to buy at TheStreet Ratings. BMC Software ( BMC) was upgraded from underweight to neutral at JPMorgan. Valuation call, based on a $34 price target. Continental Resources ( CLR) was initiated with a buy rating at Dahlman Rose. $75 price target. Bakken shale should continue to drive growth. DTE Energy ( DTE) was upgraded from neutral to outperform at Credit Suisse. Improved state regulation should help drive earnings growth. $59 price target. Gen-Probe ( GPRO) was initiated with a buy rating at Deutsche Bank. $70.50 price target. Company is a market leader and new products should drive growth in 2012. Groupon ( GRPN) was initiated with a hold rating at Stifel Nicolaus. Stock is already discount several years of hyper growth. Coverage of Groupon was started with an outperform rating at Barrington Research. $30 price target. Company is a market leader and has significant scale. Kirby ( KEX) was initiated with an overweight rating at Evercore. $74 price target. Double-digit EPS growth likely to continue through 2013 driven by strong demand fundamentals.
Lazard ( LAZ) was upgraded from neutral to outperform at Credit Suisse said. Valuation call, based on a $31 price target. Louisiana-Pacific ( LPX) was downgraded to reduce at TD Securities. Valuation call, as the stock is up 64% since October. $6.50 price target. Coverage of Madison Square Garden ( MSG) was started with a buy rating at Needham. $37 price target. Stock is attractive on a sum-of-the-parts basis. Vail Resorts ( MTN) was initiated with an outperform rating at Credit Suisse. $56 price target. Demand remains strong from high-end travelers. Children's Place ( PLCE) was downgraded from buy to neutral at Sterne Agee. Company is facing increased competition and merchandising could be hurt by weather trends. $60 price target. Pinnacle West ( PNW) was downgraded from outperform to neutral at Credit Suisse. Valuation call, based on a $52 price target. Spirit Aerosystems ( SPR) was upgraded from neutral to outperform at Credit Suisse. $27 price target. Company should generate positive free cash flow in 2012. Torchmark ( TMK) was upgraded from underperform to neutral at Credit Suisse. Valuation call. Viropharma ( VPHM) was initiated with a neutral rating at Goldman Sachs. $26 price target. Company lacks near-term catalysts.